Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Clinical course of intoxication with the new anticonvulsant drug perampanel.

Hoppner AC, Fauser S, Kerling F.

Epileptic Disord. 2013 Sep;15(3):362-4. doi: 10.1684/epd.2013.0598.

PMID:
24001596
[PubMed - indexed for MEDLINE]
2.

Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.

Gidal BE, Ferry J, Majid O, Hussein Z.

Epilepsia. 2013 Aug;54(8):1490-7. doi: 10.1111/epi.12240. Epub 2013 Jun 17.

PMID:
23772853
[PubMed - indexed for MEDLINE]
3.

Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.

Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, Squillacote D, Yang H, Zhu J, Laurenza A.

Epilepsia. 2013 Aug;54(8):1481-9. doi: 10.1111/epi.12212. Epub 2013 May 10.

PMID:
23663001
[PubMed - indexed for MEDLINE]
4.

Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, Yang H, Squillacote D, Edwards HB, Zhu J, Laurenza A.

Neurology. 2012 May 1;78(18):1408-15. doi: 10.1212/WNL.0b013e318254473a. Epub 2012 Apr 18.

PMID:
22517103
[PubMed - indexed for MEDLINE]
5.

Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.

Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, Yang H, Gee M, Zhu J, Laurenza A.

Epilepsia. 2013 Jan;54(1):126-34. doi: 10.1111/j.1528-1167.2012.03648.x. Epub 2012 Aug 20.

PMID:
22905878
[PubMed - indexed for MEDLINE]
6.

Perampanel: a novel antiepileptic for the adjunctive treatment of refractory partial onset seizures.

Owen RT.

Drugs Today (Barc). 2013 Jan;49(1):23-31. doi: 10.1358/dot.2013.49.1.1906424. Review.

PMID:
23362493
[PubMed - indexed for MEDLINE]
7.

Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.

French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, Laurenza A.

Epilepsia. 2013 Jan;54(1):117-25. doi: 10.1111/j.1528-1167.2012.03638.x. Epub 2012 Aug 20.

PMID:
22905857
[PubMed - indexed for MEDLINE]
8.

Tolerability and safety of perampanel: two randomized dose-escalation studies.

Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D.

Acta Neurol Scand. 2012 Jan;125(1):8-15. doi: 10.1111/j.1600-0404.2011.01588.x. Epub 2011 Aug 29.

PMID:
21883097
[PubMed - indexed for MEDLINE]
9.

Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures.

Ko D, Ramsay RE.

Acta Neurol Scand Suppl. 2013;(197):36-43. doi: 10.1111/ane.12103. Review.

PMID:
23480155
[PubMed - indexed for MEDLINE]
Free Article
10.

Novel treatment options for epilepsy: focus on perampanel.

Franco V, Crema F, Iudice A, Zaccara G, Grillo E.

Pharmacol Res. 2013 Apr;70(1):35-40. doi: 10.1016/j.phrs.2012.12.006. Epub 2013 Jan 1. Review.

PMID:
23287426
[PubMed - indexed for MEDLINE]
11.

Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.

Rektor I.

Expert Opin Pharmacother. 2013 Feb;14(2):225-35. doi: 10.1517/14656566.2013.754883. Epub 2012 Dec 23. Review.

PMID:
23259931
[PubMed - indexed for MEDLINE]
12.

Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.

French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA.

Neurology. 2012 Aug 7;79(6):589-96. doi: 10.1212/WNL.0b013e3182635735. Epub 2012 Jul 25.

PMID:
22843280
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Perampanel: as adjunctive therapy in patients with partial-onset seizures.

Plosker GL.

CNS Drugs. 2012 Dec;26(12):1085-96. doi: 10.1007/s40263-012-0021-2. Review.

PMID:
23179642
[PubMed - indexed for MEDLINE]
14.

The adverse event profile of perampanel: meta-analysis of randomized controlled trials.

Zaccara G, Giovannelli F, Cincotta M, Verrotti A, Grillo E.

Eur J Neurol. 2013 Aug;20(8):1204-11. doi: 10.1111/ene.12170. Epub 2013 Apr 23. Review.

PMID:
23607817
[PubMed - indexed for MEDLINE]
15.

AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel.

Zaccara G, Giovannelli F, Cincotta M, Iudice A.

Expert Rev Neurother. 2013 Jun;13(6):647-55. doi: 10.1586/ern.13.46. Review.

PMID:
23739002
[PubMed - indexed for MEDLINE]
16.

Safety and tolerability of perampanel: a review of clinical trial data.

Serratosa JM, Villanueva V, Kerling F, Kasper BS.

Acta Neurol Scand Suppl. 2013;(197):30-5. doi: 10.1111/ane.12102.

PMID:
23480154
[PubMed - indexed for MEDLINE]
Free Article
17.

Reversible pitch perception deficit due to carbamazepine.

Kashihara K, Imai K, Shiro Y, Shohmori T.

Intern Med. 1998 Sep;37(9):774-5. Review.

PMID:
9804087
[PubMed - indexed for MEDLINE]
Free Article
18.

Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.

Trevathan E, Kerls SP, Hammer AE, Vuong A, Messenheimer JA.

Pediatrics. 2006 Aug;118(2):e371-8. Epub 2006 Jul 17.

PMID:
16847080
[PubMed - indexed for MEDLINE]
Free Article
19.

Development of perampanel in epilepsy.

Satlin A, Kramer LD, Laurenza A.

Acta Neurol Scand Suppl. 2013;(197):3-8. doi: 10.1111/ane.12098. Review.

PMID:
23480150
[PubMed - indexed for MEDLINE]
Free Article
20.

Adverse effects and safety profile of perampanel: a review of pooled data.

Rugg-Gunn F.

Epilepsia. 2014 Jan;55 Suppl 1:13-5. doi: 10.1111/epi.12504. Review.

PMID:
24400692
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk